Source link : https://www.newshealth.biz/health-news/trk-inhibitor-active-in-treatment-refractory-glioblastoma/
HOUSTON — A fourth of patients with TRK fusion primary central nervous system tumors responded to the TRK inhibitor larotrectinib (Vitrakvi), including almost 40% of pediatric patients, pooled data from two studies showed. Overall, 15 of 55 (27%) patients had objective responses, including three complete responses. The 38 pediatric patients included in the analysis had […]
Author : News Health
Publish date : 2024-11-27 13:00:00
Copyright for syndicated content belongs to the linked Source.